

Jong-In Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1076045/publications.pdf>

Version: 2024-02-01

39
papers

6,020
citations

394421

19
h-index

302126

39
g-index

39
all docs

39
docs citations

39
times ranked

15827
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> ^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	1.6	145
3	The Ras/Raf/MEK/Extracellular Signal-Regulated Kinase Pathway Induces Autocrine-Paracrine Growth Inhibition via the Leukemia Inhibitory Factor/JAK/STAT Pathway. <i>Molecular and Cellular Biology</i> , 2003, 23, 543-554.	2.3	119
4	MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. <i>Seminars in Oncology</i> , 2015, 42, 849-862.	2.2	96
5	Raf/MEK/ERK can regulate cellular levels of LC3B and SQSTM1/p62 at expression levels. <i>Experimental Cell Research</i> , 2014, 327, 340-352.	2.6	90
6	A Mortalin/HSPA9-Mediated Switch in Tumor-Suppressive Signaling of Raf/MEK/Extracellular Signal-Regulated Kinase. <i>Molecular and Cellular Biology</i> , 2013, 33, 4051-4067.	2.3	81
7	Noncatalytic Function of ERK1/2 Can Promote Raf/MEK/ERK-mediated Growth Arrest Signaling. <i>Journal of Biological Chemistry</i> , 2009, 284, 33006-33018.	3.4	73
8	IFI16 Is an Essential Mediator of Growth Inhibition, but Not Differentiation, Induced by the Leukemia Inhibitory Factor/JAK/STAT Pathway in Medullary Thyroid Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 4913-4920.	3.4	48
9	Mitochondria-Targeted Nitroxide, Mito-CP, Suppresses Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1529-1540.	3.6	44
10	Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. <i>Frontiers in Biology</i> , 2014, 9, 95-103.	0.7	44
11	Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5436.	4.1	44
12	Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. <i>Cancer Letters</i> , 2010, 297, 31-41.	7.2	43
13	The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. <i>Experimental Cell Research</i> , 2011, 317, 2671-2682.	2.6	41
14	Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2069.	4.1	40
15	Interleukin-1 β can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. <i>Cytokine</i> , 2005, 29, 125-134.	3.2	32
16	The Role of STAT3 in Thyroid Cancer. <i>Cancers</i> , 2014, 6, 526-544.	3.7	27
17	Sp1 regulates Raf/MEK/ERK-induced p21 ^{CIP1} transcription in TP53-mutated cancer cells. <i>Cellular Signalling</i> , 2015, 27, 479-486.	3.6	27
18	Mortalin (HSPA9) facilitates <i>BRAF</i> -mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability. <i>Science Signaling</i> , 2020, 13, .	3.6	24

#	ARTICLE	IF	CITATIONS
19	A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. <i>Cellular Signalling</i> , 2018, 42, 11-20.	3.6	22
20	Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. <i>Oncogene</i> , 2020, 39, 4257-4270.	5.9	22
21	ERK1/2 can feedback-regulate cellular MEK1/2 levels. <i>Cellular Signalling</i> , 2015, 27, 1939-1948.	3.6	21
22	AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. <i>Experimental Cell Research</i> , 2013, 319, 1732-1743.	2.6	20
23	Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells. <i>Molecular and Cellular Biology</i> , 2017, 37, .	2.3	20
24	Suppression of B-Raf ^{V600E} melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. <i>Cancer Biology and Therapy</i> , 2017, 18, 106-114.	3.4	20
25	Active ERK2 is sufficient to mediate growth arrest and differentiation signaling. <i>FEBS Journal</i> , 2015, 282, 1017-1030.	4.7	19
26	Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. <i>Endocrinology and Metabolism</i> , 2015, 30, 593.	3.0	17
27	Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. <i>Cancer Biology and Therapy</i> , 2017, 18, 473-483.	3.4	17
28	GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. <i>Experimental Cell Research</i> , 2004, 303, 79-88.	2.6	15
29	Autophagy sensitivity of neuroendocrine lung tumor cells. <i>International Journal of Oncology</i> , 2013, 43, 2031-2038.	3.3	15
30	Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. <i>Genes and Genomics</i> , 2014, 36, 829-841.	1.4	15
31	Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. <i>Cancer Letters</i> , 2013, 339, 144-151.	7.2	14
32	Phosphoinositide and Erk signaling pathways mediate activity-driven rodent olfactory sensory neuronal survival and stress mitigation. <i>Journal of Neurochemistry</i> , 2015, 134, 486-498.	3.9	14
33	Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells. <i>Cancer Letters</i> , 2021, 502, 25-33.	7.2	11
34	Pediatric Medullary Thyroid Carcinoma. <i>Journal of Pediatric Oncology</i> , 2016, 3, 29-37.	0.1	10
35	Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3002-3002.	1.6	10
36	Analogues of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1063.	4.1	9

#	ARTICLE	IF	CITATIONS
37	Treatment of Cells and Tissues with Chromate Maximizes Mitochondrial 2Fe2S EPR Signals. International Journal of Molecular Sciences, 2019, 20, 1143.	4.1	5
38	Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats. Transplantation Direct, 2020, 6, e584.	1.6	4
39	eIF5A-Independent Role of DHPS in p21CIP1 and Cell Fate Regulation. International Journal of Molecular Sciences, 2021, 22, 13187.	4.1	1